Interesting Images18F-FDG and 68Ga-FAPI-04 PET/CT in Evaluating Clear-Cell Endometrial CancerKiran, Murat Yilmaz MD; Has Simsek, Duygu MD; Sanli, Yasemin MD; Kuyumcu, Serkan MD Author Information From the Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Received for publication May 27, 2022; revision accepted November 1, 2022. Conflicts of interest and sources of funding: none declared. Correspondence to: Murat Yilmaz Kiran, MD, Istanbul Tip Fakültesi, Nükleer Tip Anabilim Dali 34093 Fatih, Istanbul, Turkey. E-mail: [email protected]. Clinical Nuclear Medicine 48(2):p e87-e88, February 2023. | DOI: 10.1097/RLU.0000000000004532 Buy Metrics Abstract A 60-year-old woman diagnosed with clear cell endometrial carcinoma received neoadjuvant chemotherapy. However, the patient was inoperable and referred to our clinic to evaluate the extent of the disease. The patient underwent 18FDG PET/CT and 68Ga-FAPI (fibroblast activated protein inhibitor)-04 PET/CT scans. 68Ga-FAPI-04 PET/CT outperformed 18FDG PET/CT demonstrating higher uptake in the metastatic lesions. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.